Cytokine-like protein 1–induced survival of monocytes suggests a combined strategy targeting MCL1 and MAPK in CMML
Open Access
- 17 June 2021
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 137 (24) , 3390-3402
Abstract
Mouse models of chronic myeloid malignancies suggest that targeting mature cells of the malignant clone disrupts feedback loops that promote disease expansion. Here, we show that in chronic myelomonocytic leukemia (CMML), monocytes that accumulate in the peripheral blood show a decreased propensity to die by apoptosis. BH3 profiling demonstrates their addiction to myeloid cell leukemia-1 (MCL1), which can be targeted with the small molecule inhibitor S63845. RNA sequencing and DNA methylation pattern analysis both point to the implication of the mitogen-activated protein kinase (MAPK) pathway in the resistance of CMML monocytes to death and reveal an autocrine pathway in which the secreted cytokine-like protein 1 (CYTL1) promotes extracellular signal-regulated kinase (ERK) activation through C-C chemokine receptor type 2 (CCR2). Combined MAPK and MCL1 inhibition restores apoptosis of monocytes from patients with CMML and reduces the expansion of patient-derived xenografts in mice. These results show that the combined inhibition of MCL1 and MAPK is a promising approach to slow down CMML progression by inducing leukemic monocyte apoptosis.Keywords
This publication has 46 references indexed in Scilit:
- Phase 1 study of lenzilumab, a recombinant anti–human GM-CSF antibody, for chronic myelomonocytic leukemiaBlood, 2020
- Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic myelomonocytic leukemiaLeukemia, 2020
- How I treat chronic myelomonocytic leukemiaBlood, 2017
- Engraftment of chronic myelomonocytic leukemia cells in immunocompromised mice supports disease dependency on cytokinesBlood Advances, 2017
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemiaBlood, 2016
- Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6Nature, 2015
- Treatment of Chronic Myelogenous Leukemia by Blocking Cytokine Alterations Found in Normal Stem and Progenitor CellsCancer Cell, 2015
- Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AMLCell, 2012
- The landscape of somatic copy-number alteration across human cancersNature, 2010
- MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2.Proceedings of the National Academy of Sciences, 1993